Tuesday, June 9, 2026
← Back to archivePolicy
Policy•KFF•Jun 9, 2026
Can AI Break the “Measurement Paradigm?”
background ▾
- •Reliable measurement of AI's impact on patient outcomes remains a foundational challenge for healthcare implementation and payment reform
Mass General BrighamBrigham and Women's Hospital
→ Read original articlePolicy•STAT News•Jun 9, 2026
A leader of the 2014 U.S. Ebola response compares then to now
background ▾
- •USAID dismantling removed ~200 people from DRC mission and thousands of partner networks, eliminating early-warning capacity and delaying outbreak detection by 10 days (WHO notification May 5 vs. U.S. notification May 15)
- •Current Ebola outbreak spreading 12x faster than 2014 (300 confirmed cases in 2 weeks vs. 2.5 months), projected to reach 20,000 cases, while U.S. response capacity is significantly degraded
- •Loss of institutional knowledge from previous crises and inability to rapidly mobilize critical interventions (PPE, lab support, contact tracing, safe burial training) that were developed and refined during 2014 response
Policy•STAT News•Jun 9, 2026
Opinion: Why STAT is sticking with ‘health care’ as two words
background ▾
- •This is a style guide decision by a health news outlet with no regulatory, clinical, or commercial implications for the pharmaceutical industry
Policy•STAT News•Jun 9, 2026
Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
background ▾
- •Kennedy administration is systematically dismantling federally funded animal research programs (CDC primate studies, NIH funding shifts), directly threatening xenotransplantation development which critically depends on primate models to predict human organ survival
- •Xenotransplantation field has reached inflection point after 40+ years of incremental progress: gene-edited knockout pigs combined with improved immunosuppression now make clinical human trials feasible, but this advancement could be halted by policy change
- •Watch for: industry response and potential private funding replacements for xenotransplantation research; FDA's stance on whether in vitro alternatives (organs-on-chips, organoids, AI models) are acceptable surrogates for primate efficacy/safety data in xenotransplant IND applications
Policy•STAT News•Jun 9, 2026
Alcohol study discarded by Trump officials is published in scientific journal
background ▾
- •Suppressed federal alcohol research finding low-consumption health risks was published independently in peer-reviewed journal after Trump officials rejected it, raising questions about politicization of nutrition science and regulatory capture by alcohol industry lobbyists
- •2025 dietary guidelines departed from SAMHSA study conclusions, instead relying on alternative evidence that acknowledges mixed science on moderate drinking, potentially affecting public health messaging and future payer/formulary decisions on alcohol-related conditions
- •Monitor whether this published study gains traction in future guideline updates, influences state/local alcohol policy, or becomes precedent for handling controversial nutrition/public health research during political transitions
Substance Abuse and Mental Health Services Administration (SAMHSA)Department of Health and Human Services (HHS)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jun 9, 2026
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer
background ▾
- •GSK is paying a 40% premium ($124/share vs. $88.49 close) for Nuvalent's two molecules targeting genetically defined lung cancer subsets, betting on superior durability/tolerability profiles and multiblockbuster potential despite small patient populations (1-5% of NSCLC)
- •Neladalkib differentiates on side effect profile versus Pfizer's Lorbrena, citing 7-year Crown study data showing difficult tolerability in younger patient populations who require longer treatment durations—a critical value driver in GSK's valuation
- •Watch FDA approvals (September/November 2024) and phase 3 data for neladalkib versus Roche's Alecensa in TKI-naive patients; commercial uptake will depend on label expansion for zidesamtinib and ability to displace entrenched competitors (Xalkori, Rozlytrek, Lorbrena)
GSKNuvalentRochezidesamtinibneladalkibrisvutatug rezetecan
→ Read original articleMarket Access•Fierce Biotech•Jun 8, 2026
ResMed snaps up Noctrix Health in $340M sleep tech deal
background ▾
- •ResMed acquires FDA De Novo-cleared neuromodulation device (Nidra) for restless legs syndrome, a major adjacent sleep disorder, marking strategic portfolio diversification beyond CPAP and respiratory care
- •Nidra has established clinical credibility through peer-reviewed data and inclusion in American Academy of Sleep Medicine guidelines, de-risking the asset relative to typical startup medtech acquisitions
- •Critical execution question: whether ResMed's scale, distribution infrastructure, and digital health platform can successfully commercialize a wearable neuromodulation therapy beyond its historical expertise in airway pressure devices
ResMedNoctrix HealthAngelini VenturesNidra (Noctrix Motor Activation therapy)
→ Read original articleMarket Access•Fierce Biotech•Jun 8, 2026
Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger
background ▾
- •Treeline secures public market access with $900M cash runway through 2029, enabling advancement of four clinical programs and launch of seven additional programs by 2028
- •Pan-KRAS inhibitor TLN-372 positioned as lead value driver given recent competitive momentum in RAS-targeted oncology (Revolution Medicines benchmark)
- •Execution risk centers on 2027-2028 interim data readouts across BCL6, EZH2, and KRAS programs; competitive landscape in RAS inhibitors intensifying rapidly
Treeline BiosciencesStandard BioToolsEli LillyTLN-121TLN-254TLN-372
→ Read original articleMarket Access•Fierce Biotech•Jun 8, 2026
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio
background ▾
- •J&J's $1B acquisition of Firefly Bio represents a major capital commitment to DAC platform technology and KRAS-directed oncology, despite the company's recent asset pruning elsewhere in its pipeline
- •DAC space is attracting heavyweight investment across industry (Merck, Roche, BMS, Pfizer deals since 2023), yet remains preclinical for most programs with only BMS's BMS-986497 in Phase 1 trials; clinical validation is critical next inflection point
- •Watch for: Firefly's first-in-human DAC data, particularly KRAS-driven tumor efficacy and tolerability; competitive readouts from BMS-986497 and other DAC programs; and whether J&J's Firelink platform delivers on "undruggable" target promise to justify premium valuation
Johnson & JohnsonFirefly BioEli LillyBMS-986497ORM-6151
→ Read original articleMarket Access•Fierce Pharma•Jun 9, 2026
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
background ▾
- •Eli Lilly is viewed by equity analysts as gaining market share and competitive distance in obesity despite a crowded and growing competitive landscape
- •ADA conference presentations appear to have reinforced Lilly's leadership position, likely through efficacy, safety, or real-world evidence data
Eli Lilly
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 8, 2026
GSK pledges £44.5M in near term for UK biotech to explore cause of liver fibrosis regression
background ▾
- •GSK commits £44.5M upfront plus up to £118M per target milestone to Engitix for fibrosis regression target identification, signaling significant investment in novel hepatology mechanism beyond its current pipeline
- •The collaboration focuses on an underexplored area—mechanisms of fibrosis regression—rather than standard fibrosis inhibition, representing a differentiated scientific approach
- •Success will depend on translating Engitix's multi-omics datasets into validated drug targets; clinical proof-of-concept in fibrosis regression remains a high-risk, high-reward endeavor
GSKEngitixTakedaefimosferminbepirovirsen
→ Read original articleClinical Trials•Fierce Biotech•Jun 9, 2026
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
background ▾
- •BIA 28-6156 phase 2b missed primary endpoint (time to clinically meaningful motor progression) and key secondary endpoints in GBA1-variant Parkinson's patients, forcing program termination in this indication
- •Despite favorable safety data and a mechanistically sound approach targeting GCase restoration, the drug failed to demonstrate disease modification, raising questions about GCase activation as a therapeutic strategy in this patient population
- •Bial's pipeline is now materially weakened; monitor whether the company pursues BIA 28-6156 in alternative indications or considers strategic partnerships/M&A to rebuild R&D capability
BialBIA 28-6156opicaponeapomorphine
→ Read original articleClinical Trials•Fierce Biotech•Jun 8, 2026
ADA: Dexcom CGM shows benefit in non-insulin diabetes patients
background ▾
- •CGM use in non-insulin type 2 diabetes achieved 0.9% greater A1C reduction and 5 additional hours daily in target glucose range, providing first robust randomized evidence in primary care settings
- •Payer coverage remains the critical barrier; historically concentrated in insulin-dependent patients, expansion depends on evidence of durable long-term outcomes and healthcare cost reduction
- •Watch the ongoing 12-month CONNECT extension results and real-world payer coverage decisions for Dexcom G7 and competing OTC systems (Abbott's Libre Rio/Lingo) in non-insulin type 2 diabetes management
DexcomAbbottDexcom G7Dexcom SteloAbbott FreeStyle Libre
→ Read original articleClinical Trials•Fierce Pharma•Jun 9, 2026
ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes
background ▾
- •Foundayo has demonstrated efficacy in Type 2 diabetes and could capture a second major indication following its obesity approval, significantly expanding addressable market
- •Lilly's oral GLP-1 formulation is directly competing with semaglutide in a high-value therapeutic area, with data suggesting competitive or superior efficacy profiles
- •Watch for regulatory submissions and potential FDA decision timelines for Foundayo's diabetes indication, as well as real-world commercial uptake comparing oral to injectable GLP-1 agents
Eli LillyFoundayoorforglipronsemaglutide
→ Read original articleClinical Trials•Fierce Pharma•Jun 9, 2026
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
background ▾
- •Amgen is actively promoting Repatha's utility in high-risk cardiometabolic subgroups to strengthen its competitive positioning in cardiovascular/metabolic disease
- •The company is explicitly acknowledging GLP-1 drugs as competitive threats and responding with targeted clinical evidence
AmgenRepathaevolocumab
→ Read original article